Avizakimab is under clinical development by Boston Pharmaceuticals and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase II drugs for Systemic Lupus Erythematosus have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Avizakimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Avizakimab (BOS-161721) is under development for the treatment of systemic lupus erythematosus. It is administered through intravenous and subcutaneous route of administration. The drug candidate is a monoclonal antibody and acts by targeting Interleukin-21.
Boston Pharmaceuticals overview
Boston Pharmaceuticals (Boston Pharma) operates as a pharmaceutical and healthcare company that develops new drugs for unmet needs. The company products include new drug application (IND) through Phase 2 including BOS161721, BOS172738, BOS-475, BOS-371, BOS-342, BOS-857, BOS-704, BOS-421, BOS-228, and others. Its drugs are used in the therapeutic areas of tumors, cancer, bacterial infection, viral infections, oncology and auto immune. The company also acquires molecules from pharmaceutical and biotechnology companies and transform them into various therapeutics that improve patients’ lives. Boston Pharma is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Avizakimab’s drug-specific PTSR and LoA scores, buy the report here.